Core Viewpoint - Meizhong Jiahe (02453) has seen a significant stock price increase of 6.12%, reaching HKD 2.08, following the announcement of its subsidiary Guangzhou Taihe Oncology Hospital being approved to enter the "Hong Kong-Macao Drug and Medical Device Access" list, enhancing its competitive edge in the oncology sector [1] Group 1 - The approval from the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration allows the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the capability to utilize innovative drugs and medical devices, thereby broadening its business scope and creating a differentiated competitive advantage in the market [1] - The initiative is part of the core implementation measures of the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan," which aims to facilitate the use of clinical urgently needed drugs and advanced medical devices in designated medical institutions [1]
美中嘉和高开逾6% 子公司广州泰和肿瘤医院获批进入“港澳药械通”指定医疗机构名单